Brioli, A
Perrone, G
Patriarca, F
Pezzi, A
Nobile, F
Ballerini, F
Motta, M R
Ronconi, S
Tacchetti, P
Catalano, L
Zannetti, B A
Rizzi, S
Volpe, S
Zamagni, E
Liberati, A M
Mancuso, K
Boccadoro, M
Davies, F E
Morgan, G J
Palumbo, A
Cavo, M
Article History
Received: 18 August 2014
Revised: 29 November 2014
Accepted: 2 December 2014
First Online: 2 February 2015
Competing interests
: AB has received honoraria from Celgene, MC has received honoraria and served on speakers’ bureaux for Janssen-Cilag, Millennium Pharmaceuticals, Celgene and Novartis and has been a consultant for Janssen-Cilag and Millennium Pharmaceuticals. FP has received honoraria from Janssen-Cilag, Celgene, Schering-Plough and Roche; AP has served on an advisory committee for Celgene, Janssen-Cilag, Amgen, Bristol-Myers Squibb, Millenium and Onyx and has received honoraria from Celgene, Janssen-Cilag, Bristol-Myers Squibb, Millenium, Onyx and Amgen; MB has received honoraria from Novartis and Bristol-Myers Squibb. The remaining authors declare no conflict of interest.